CAR-T therapy engineers a patient's T cells to express chimeric antigen receptors targeting:
- Bacterial antigens
- Viral proteins
- Tumor-specific antigens
- Autoantigens
Answer: Tumor-specific antigens
CAR-T cells recognize cancer cell surface markers (e.g., CD19 in B-cell malignancies), triggering targeted destruction. Personalized immunotherapy with high response rates in refractory cancers. Approved for certain leukemias/lymphomas. [[ICMR Reports, NCERT Biology Class 12]]